What is it about?
Over the last 20 years, new drug therapies for lymphomas of B cells and T cells have expanded considerably. This article focuses on specific therapies that target the lymphoma ceullular and epigenetic signaling pathways, immunotherapy.
Featured Image
Why is it important?
New therapy options increase both survival outcome and duration of response, may reduce toxicities from conventional therapies, may be an effective option in relapsed or refractory disease.
Perspectives
The efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities. Further opportunities are warranted to identify patients who are most likely to achieve durable response and reduce the risk of disease progression
Dr. Clement Chung
Houston Methodist
Read the Original
This page is a summary of: Current targeted therapies in lymphomas, American Journal of Health-System Pharmacy, October 2019, Oxford University Press (OUP),
DOI: 10.1093/ajhp/zxz202.
You can read the full text:
Contributors
The following have contributed to this page
